ECLYPse

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Apr 13, 2024 → Oct 24, 2026

Cited window

Oct 10, 2026 → Oct 24, 2026

Retrieved

Oct 29, 2026

Title

Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

Registry

NCT06640166

Study IDs

6070 · 2023-508615-24-00

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Collaborators

Pierre Fabre Pharma GmbH

Design

Phase 2 · Interventional, single group

Status

Recruiting

Enrollment

25 estimated

Start

2024-06-03 actual

Primary completion

2025-12-31 estimated

Primary endpoint

6-month Progression Free Survival rate

Interventions

1 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –1 matching source (1 X thread) could not be read and is not included.
• –Not yet captured in this edition: a view on continuing targeted therapy beyond progression with chemotherapy and the need for more translational evidence.
• –Not yet captured in this edition: a view on continuing encorafenib plus cetuximab beyond progression with FOLFIRI and the need for more translational data.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –10 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –This report reflects the sources reviewed for this edition, not all public discussion or the prevalence of views among HCPs. Reposts should not be counted as independent endorsements.
• –One discussion could not be read, two potentially relevant passages were not fully assessed, and some additional comments could not be confidently attributed. Further qualifications or consequential views may therefore be absent.
• –No exact-trial results publication or protocol was available, and no regulatory label for the precise combination was identified. The commentary cannot establish approved use or independently resolve comparative benefit.
• –The reported treatment lines and six-month PFS percentages differ across sources and cannot be reconciled from the available statements.
• –The proof-of-concept sample and endpoint-evaluable denominator are small, OS is described as immature or not reached, and the reviewed commentary provides no tolerability assessment. Favorable efficacy interpretations should not be read as settled comparative or safety conclusions.

How reports are built and checked: Methods.

Last checked for new commentary Oct 29, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "ECLYPse" (NCT06640166), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "eclypse-06640166". If you cannot make requests, read https://www.erudio.com/reports/eclypse-nct06640166.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06640166", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06640166 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/eclypse-nct06640166.json
curl https://www.erudio.com/reports/eclypse-nct06640166.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "eclypse-06640166" })